"Hence, I’m inclined to agree that ITMN’s chances for eventual approval are very good even if they come up short on the current review cycle."
Does this make you fairly bearish though short-term? If one believes the FDA is going to reject the drug the first time, the stock probably has a good bit of downside although I'm not certain how much of the market cap is tied to this drug compared to the HCV compound.
Market Data 
Markets 
AI
